Bitterroot Bio Announces Appointment of Georgette Verdin as Chief People Officer and Sherwin Chen as Chief Legal Officer and Corporate Secretary PALO ALTO, Calif. and NEEDHAM, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a pioneering biotechnology company focused on developing innovative medicines in the field of...

Bitterroot Bio Announces Dosing of First Participants in a Phase 1, First-in-Human Study of BRB-002 in Healthy Volunteers PALO ALTO, Calif. and MELBOURNE, Australia, April 29, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced that the...

Bitterroot Bio and Biotheus Announce Research Collaboration to Develop Bispecific Proteins in Cardio-Immunology PALO ALTO, Calif., and ZHUHAI, China, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and...

Bitterroot Bio to Present Preclinical Research at American Heart Association Conference PALO ALTO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Bitterroot Bio, a biotechnology company focused on developing novel immunotherapies in cardiovascular disease, has been selected to present...

Bitterroot Bio Launches Out of Stealth with $145 Million Series A Financing to Develop Transformative Medicines in Cardio-immunology Founders, Executive Team, and Advisors are recognized scientific and clinical pioneers in the fields of immunology and cardiology Series A financing co-led by ARCH Venture Partners and Deerfield...